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Abstract 
Mechanisms contributing to treatment resistant depression (TRD) and major depressive disorder 
(MDD) are poorly understood. Identifying peripheral biomarkers in an easily accessible tissue, such as whole 
blood, will enhance the mechanistic understanding of these disorders and could potentially establish targets for 
personalized treatment development. It has been shown that CpG methylation-based epigenetic modifications 
in the brain are associated with stress-related phenotypes. Therefore, the first portion of the current study 
sought to identify CpG methylation-based peripheral biomarkers of TRD concordant with brain CpG 
methylation in the rat, in a hormone-induced model of TRD.   
Many factors, both environmental and biological, can alter CpG methylation in blood and/or brain 
tissues in eukaryotes. This differential CpG methylation is a well-documented functional mechanism by which 
genes are differentially expressed. Depending on the specific gene, this functional alteration of expression can 
have downstream physiological and phenotypic effects. Taking into account the need to identify peripheral 
biomarkers of MDD in humans, the second portion of the current study sought to identify the association 
between lifetime MDD diagnosis status and peripheral, blood-derived methylation and expression. Finally, 
supplementary analyses of publically available datasets highlight the association between neuronal CpG 
methylation and lifetime MDD diagnosis status and using a cohort of deceased subjects with balanced 
prevalence of lifetime MDD cases and “healthy” controls, as well as intra-subject brain and blood CpG 
methylation correlations in  “healthy” controls. 
The current study identified one salient peripheral biomarker for TRD that is concordant in CNS 
tissue, as well as one potential peripheral biomarker for MDD. In the TRD rat model, the first CpG site 
upstream of the transcription start site (TSS) in the promoter region of Slc6a3 was differentially methylated 
between case and control group animals in both mPFC and whole blood. Second, using blood drawn from 
human participants from the Detroit Neighborhood Health Study, SLC6A4 mRNA expression approached a 
significant association with lifetime MDD diagnosis status. Efforts to elucidate additional peripheral 
biomarkers should continue to expand to include polygenic CpG methylation measurements in multiple 
tissues. 
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Chapter 1: Introduction 
Both major depressive disorder (MDD) and treatment resistant depression (TRD) are mood disorders 
that manifest heterogeneously in regards to risk factors, onset, symptoms, and treatment response1. To be 
diagnosed with MDD a patient must exhibit two or more weeks of five of the following symptoms as a 
departure from their basal state: significant unintentional weight loss/gain, significant differential sleep 
patterns, irritability, fatigue/energy loss, feelings of worthlessness/guilt, difficulty concentrating/thinking, or 
recurring thoughts of self-harm/suicide, with at least one of the symptoms being either anhedonia and/or 
depressed mood2. Lifetime prevalence of MDD in the United States (US) is estimated at ~16%, and past year 
prevalence of MDD is estimated at ~6% in the US3. MDD is commonly comorbid with anxiety, substance 
abuse, and personality disorders4, and patients afflicted with MDD are at a significantly heightened risk for 
suicide completion compared to the general population5. MDD is also considered the leading cause of non-
fatal disease burden in the world6.  
Numerous treatment options exist for patients with MDD, including deep brain stimulation, 
electroconvulsive therapy, psychotherapy, and pharmacological intervention. The most common treatment 
course is pharmacological intervention by way of tricyclic antidepressants (TCAs), monoamine oxidase 
inhibitors (MAOIs), selective serotonin (5HT) and norepinephrine (NE) reuptake inhibitors (SNRIs), or 
selective 5HT reuptake inhibitors (SSRIs). Although a wide range of pharmacological treatment options exist, 
only 30-50% of patients reach remission with appropriate use7,8, and 10-20% of care-seeking patients remain 
significantly symptomatic even after two years of treatment9. Clinical diagnosis of TRD is typical after failed 
pharmacological intervention with two separate classes of antidepressants10. The personal and societal costs of 
TRD compared to MDD are great: patients with TRD spend more time in medical care, have an increased 
quantity of comorbid disorders, and are more likely to experience thoughts of self-harm/suicide11.  
Hypothalamic-pituitary-adrenal (HPA) axis hyperactivation is a common and well-characterized 
phenomenon in both TRD and MDD12. The HPA axis involves a neuroendocrine negative feedback loop in 
which corticotropin release hormone (CRH) is released from the hypothalamus in response to psychological 
stress. This stimulates the anterior pituitary to release adrenocorticotropin hormone (ACTH), which signals the 
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adrenal cortices to release cortisol (CORT). High CORT levels contribute to a negative feedback mechanism in 
the HPA axis, as they result in an inhibition of CRH release from the hypothalamus and ACTH from the 
anterior pituitary. Importantly, a meta-analytic study including over 18,000 participants across 361 original 
studies determined that depressed individuals displayed elevated levels of both CORT and ACTH compared to 
“healthy” controls1. 
The genes SLC6A3 and SLC6A4, the protein products that they encode, and the neurotransmitters that 
the proteins interact with have also been implicated in the etiology of MDD, TRD, and other mental health 
disorders. SLC6A3 and SLC6A4 encode the dopamine (DA) and the 5HT reuptake transporter proteins, 
respectively (DAT and SERT). These membrane-bound sodium-dependent transport proteins function to 
traffic DA and 5HT from the synaptic cleft back into the presynaptic neuron for metabolism or 
reuse/repackaging. Buproprion, an NE and DA reuptake inhibitor, is commonly used to treat depression and 
other mood disorders. The mechanism of action of Buproprion is antagonism of DAT. This mechanism has 
been shown to increase extracellular levels of DA in the nucleus accumbens (NAC)13 and the prefrontal cortex 
(PFC) in rodent models of depression14. SSRI’s are another common class of antidepressants used to treat 
many types of depression and mood disorders. SSRIs act mechanistically to antagonize SERT, thereby 
inhibiting the reuptake of 5HT from the cleft and providing an increased quantity of 5HT for the postsynaptic 
neuron to utilize. Importantly, a previously validated ACTH-induced treatment-resistant depression model in 
the rat15 showed significantly different extracellular 5HT and DA levels in the PFC of ACTH-exposed animals 
compared to saline-exposed control animals after the stress of a Porsolt forced swim test (FST). Specifically, 
the extracellular DA PFC levels of ACTH-exposed animals were decreased compared to controls, whereas the 
extracellular 5HT PFC levels of ACTH-exposed animals were increased compared to controls. This model 
also showed that a common TCA (Imipramine) did not rescue chronic ACTH-exposed animals immobility 
time in the FST compared to animals exposed chronically to ACTH, and no Imipramine, suggesting an 
endophenotype of depression-like behaviors that is resistant to TCA16. Additionally, hyper-ACTH activation in 
patients with Cushing’s disease leads to an increased occurrence of depression resistant to TCA treatment17,18. 
These results provide strong evidence that through chronic ACTH exposure in rodents, neurotransmitter 
alterations occur which may mimic TRD in humans. 
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In humans, sequence variations in the SLC6A3 and SLC6A4 genes have been associated with MDD 
status19. These sequence variations have also been associated with differential expression of the mRNA 
transcripts mapping to these genes20,21, although inconsistencies in the literature have been reported. 
Regardless, these sequence variations are static in nature and do not account for interaction of environmental 
factors (such as stress) that may affect these systems. One mechanism that helps to explain environmental 
factors affecting physiological systems is DNA methylation: the covalent addition of a methyl group to the 5’ 
position of a cytosine residue, typically where cytosine is adjacent to a guanine residue (i.e. CpG methylation). 
CpG methylation functions as a regulator of transcriptional activity in both eukaryotes and prokaryotes. This 
function is especially salient when differential CpG methylation occurs in the region directly upstream of the 
transcription start site (promoter region), which can be rich in CpG residues (CpG island) compared to other 
regions of the genome. Increased CpG methylation of a CpG island in a promoter region can sterically inhibit 
the association of polymerases and transcription factors functioning to transcribe mRNA22, thereby facilitating 
a reduction in expression of the downstream locus.  
Taking into account the great personal and societal costs of the TRD and MDD, it is apparent that 
characterizing the underlying neurobiological mechanisms of both disorders is necessary. However, significant 
hurdles remain that inhibit this desired progress. Primarily, the inability to access central nervous system 
(CNS) tissue of living patients creates an inability to assay these etiological tissues. In turn, this key deficiency 
creates a need to identify salient peripheral biomarkers of depression in humans (such as in the blood or 
saliva), and to utilize animal models in which CNS biomarkers of TRD can be compared to peripheral 
biomarkers; however, current research has yet to determine the degree to which peripheral biomarkers 
correspond to relevant CNS biomarkers of the disorders23,24.  
To address these gaps in knowledge, we have undertaken a three-pronged approach in this research 
project. Utilizing the previously validated ACTH-induced TRD model in the rat15,16, the first portion of the 
current study assays CpG methylation of Slc6a3 and Slc6a4 promoter regions in rat whole blood and compares 
it to CpG methylation in medial PFC (mPFC), in order to identify CNS-relevant peripheral biomarkers of 
TRD. Our working hypothesis is that ACTH-exposed animals (case group) will exhibit significantly differential 
CpG methylation in the promoter regions near the TSS of Slc6a3 and Slc6a4 genes in mPFC tissue and whole 
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blood, compared to control group animals. Additionally, we hypothesize that mPFC CpG methylation in both 
case and control group animals will significantly correlate with intra-group measurements of CpG 
methylation in whole blood.  
The second portion of the current study utilizes available genomic data from the Detroit 
Neighborhood Health Study (DNHS) in order to investigate the relationship between peripheral measures of 
CpG methylation, peripheral measures of mRNA transcription, and lifetime MDD diagnosis status. The DNHS 
is a longitudinal epidemiological study of adults from Detroit, Michigan26,27. Participants were interviewed via 
phone, and demographic, socio-economic, and standard assessments of MDD were administered. Additionally, 
whole blood was collected for genome-wide methylation and expression assays, as well as other genomic data 
collection. The second portion of the current study hypothesizes that CpG methylation of probes mapping to 
the human promoter regions near the TSS of SLC6A3 and SLC6A4 genes will be significantly associated with 
mRNA expression of probes mapping to their respective genes. Additionally, we hypothesize that mRNA 
expression of probes mapping to the human SLC6A3 and SLC6A4 genes will be significantly associated with 
lifetime MDD diagnosis status. Finally, we hypothesize that CpG methylation of probes mapping to the 
promoter regions near the TSS of human SLC6A3 and SLC6A4 genes will be significantly associated with 
lifetime MDD diagnosis status.  
The third portion of the current study utilizes a publically available dataset in which genome-wide 
neuronal CpG methylation was profiled in frontal cortex from deceased MDD patients, as well as “healthy” 
controls (GEO Accession No. GSE41826), in order to test the association between brain CpG methylation and 
lifetime MDD diagnosis status. The third portion of the current study therefore hypothesizes that frontal cortex 
neuronal CpG methylation of probes mapping to the promoter regions near the TSS of the human SLC6A4 
gene will be significantly associated with lifetime MDD diagnosis status. 
Finally, to complement the human-based analyses of DNHS and GEO-derived data, and to investigate 
whether CpG methylation levels in the blood are related to CpG methylation levels in CNS tissues within our 
loci and tissues of interest, we undertook additional secondary analyses of publically available data. To 
highlight intra-subject brain and blood CpG methylation correlations, we used the Blood Brain DNA 
Methylation Comparison Tool available at http://epigenetics.iop.kcl.ac.uk/bloodbrain28. The final portion of the 
	 5	
current study therefore hypothesizes that CpG methylation of probes mapping to the promoter regions of 
human SLC6A3 and SLC6A4 genes will show significant correlations within subjects, between blood and PFC 
tissue.  
In summation of the aforementioned hypotheses, the current study offers a model by which CpG 
methylation and mRNA expression relate to depression phenotypes in both humans and rats (Figure 1).  
 In relationship A. of the model, differential CpG methylation is associated with differential mRNA 
expression. In relationship B. of the model, differential mRNA expression is associated with depression 
phenotypes. Finally, in relationship C. of the model, differential CpG methylation is associated with depression 
phenotypes in both humans and rats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic model of hypothesized effects between CpG methylation, mRNA 
expression, and depression phenotypes in human and rat.  
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Chapter 2: Methods 
ACTH-Induced Treatment-Resistant Depression Model in the Rat 
 The first phase of the current study utilized brain tissue and whole blood harvested from a previously 
validated ACTH treatment model of TRD in rats15,16, provided by collaborator Dr. Susannah Tye. Briefly, case 
animals (n = 12) were injected daily with ACTH (100ug/day) dissolved in distilled water (1mL total volume). 
Control animals (n = 13) were injected daily with 0.9% saline (1mL total volume). After 14 days, animals were 
sacrificed via i.p. injection of sodium pentobarbitone (0.4mL). 200-300uL of cardiac whole blood was 
collected from each subject post-mortem. Additionally, whole brains were removed from the subjects. mPFC 
tissue was sectioned and snap frozen. For all subjects, whole blood and mPFC tissues were shipped to the 
Uddin Lab Group on dry ice. Genomic DNA was then isolated from samples using the Qiagen Animal Blood 
and Tissue DNA kit (Catalogue No. 69504; Qiagen, Hilden, Germany). The silica-based membrane spin-
column protocol was used for all tissues and samples following manufacturer’s recommended protocol. After 
isolation, genomic DNA quantity and quality were assessed using spectrophotometry (NanoDrop) methods. 
NanoDrop concentrations for whole blood isolated genomic DNA ranged from 12.58 ng/uL to 95.05 ng/uL. 
NanoDrop concentrations for mPFC isolated genomic DNA ranged from 88.64 ng/uL to 220.80 ng/uL.  
After DNA quantification and purity assessment, the isolated genomic DNA (750 ng/sample) 
underwent bisulfite conversion (BSC), using the Qiagen Epitect Bisulfite Kit (Catalogue No. 59104) and 
following the manufacturer’s recommended protocol.  In brief, BSC is used in order to enable the assay of 
CpG methylation in DNA during subsequent protocols. DNA is denatured, and unmethylated cytosine residues 
are converted to uracil with sodium bisulfite incubation; methylated cytosines remain uncoverted, resulting in 
sequence differences between methylated and unmethylated CpG sites within DNA (i.e. “Ts” vs. “Cs”). 
NanoDrop concentrations for whole blood isolated BSC DNA ranged from 1.88 ng/uL to 26.20 ng/uL. 
NanoDrop concentrations for mPFC isolated BSC DNA ranged from 2.92 ng/uL to 8.76 ng/uL. 
Polymerase chain reaction (PCR) of BSC DNA was then performed to amplify locus-specific regions 
of DNA pertaining to Slc6a329 and Slc6a430 TSS’s and CpG Islands (CGI’s). Qiagen’s Pyromark PCR Kit 
(Catalogue No. 978703) was used for all samples. All reactions were performed in duplicate using 25ng of 
sample BSC DNA per primer set in a 25uL total reaction volume. PCR primer set information for Slc6a3 and 
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Slc6a4 are provided in Table 1. Presence of desired amplicon was visually confirmed in each sample by 
loading 4.5 ul of each reaction on a 2% agarose gel. 
 
The total remaining volume of the PCR reactions was then used in bisulfite pyrosequencing to assay 
percent CpG methylation at specific CpG sites within the BSC amplified PCR fragments. For this procedure, 
two sequencing primers for each of Slc6a4 and Slc634 were generated de novo using the PyroMark Assay 
Design software (Version 2.0.1.15) based off of the predicted sequence of the PCR amplicon after BSC. The 
aforementioned sequencing primer sets enabled assay of 12 CpG sites in the Slc6a4 amplicon, and 10 CpG 
sites in the Slc6a3 amplicon. For Slc6a4, 12 Cpg sites within the first exon were assayed. This location lies 
within a CGI, with a putative transcription factor-binding site (TFBS) also present (Figure 2).  
 
 
Table 1. PCR and pyrosequencing primer sets of target Slc6a3 and Slc6a4 loci. 	
Slc6a3 primer sets Sequence 
PCR - Forward 5' - TAG GGT TAG TGG AGT AGT GGA GAT - 3' 
PCR - Reverse 5' - /BIOT/ CCC AAA TTC AAT AAC CTC TAA CTC CC - 3'  
SEQ - CpG 11-15 (BSC) 5' - AAG TTT TTA GTT TTT TTT TAT AGT - 3' 
SEQ - CpG 16-20 (BSC) 5' - GGG GTA GGT TTG TTT AGT - 3' 
    
Slc6a4 primer sets Sequence 
PCR - Forward 5' - GGA GAA ATA AAG TTT TTT GGT TTT AAA GT - 3' 
PCR - Reverse 5' - /BIOT/ ACA CCC TAA ATC CAA ACA ATC A - 3' 
SEQ - CpG 12-15 (BSC) 5' - AAG TTT TTT GGT TTT AAA GTG A - 3' 
SEQ - CpG 16-23 (BSC) 5' - TGA GGA GGT TGT TTA GAG ATT AGA - 3' 
cg01330016	
Chr17:	
28,549,806
cg26126367	
Chr17:	
28,559,497
cg05951817	
Chr17:	
28,562,142
cg22584138	
Chr17:	
28,562,220
cg03363743	
Chr17:	
28,562,474
cg14692377	
Chr17:	
28,562,685
cg05016953	
Chr17:	
28,562,813
cg25725890	
Chr17:	
28,563,054
cg26741280	
Chr17:	
28,563,089
cg10901968	
Chr17:	
28,563,108
cg27569822		
Chr17:	
28,563,119
cg18584905	
Chr17:	
28,563,300
TSS
Exon	1	(357bp)
Transcription	Factor	AP-2	Gamma	(TFAP2C)	TFBS	(612bp)
CpG	Island	(800bp)
Rat	Slc6a4	CpG12-23
Figure 2. SLC6A4 Mayo and DNHS CpG Methylation Probe Locations  
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For Slc6a3, the first ten CpG sites upstream of the TSS in the promoter region were assayed. Cpg1 is 
the first CpG site upstream of the TSS, whereas CpG10 is the tenth site upstream of the TSS (Figure 3).  
Sequencing primer set information for Slc6a4 and Slc6a3 are provided in Table 1. Bisulfite pyrosequencing 
was performed on the Qiagen Pyrosequencing Q24 Advanced machine using the Qiagen PyroMark CpG Assay 
Kit (Catalogue No. 978746). Briefly, after PCR amplification, dsDNA is denatured and the biotinylated strand 
serves as the template for the sequencing primers in the pyrosequencing reaction. This template is incubated 
with DNA polymerase, ATP sulfurylase, luciferase, and apyrase, as well as the substrates adenosine 5' 
phosphosulfate and luciferin. Deoxyribonucleotide triphosphate (dNTP) molecules are added to the sequencing 
primer on the template strand by DNA polymerase if the dNTPs are complementary to the template strand. 
When this occurs, Pyrophosphate (PPi) is cleaved from the dNTP, and the biochemical properties of the 
aforementioned factors enable the generation of light signal proportional to number of dNTPs incorporated. In 
this way, sequencing by synthesis was performed, and with BSC DNA CpG methylation ratios can be 
determined31. Locus-specific methylation values at each CpG site were recorded by the Q24 machine and 
exported to Microsoft Excel.  
Replicates exhibiting intra-sample differences greater than 5.4% were excluded from analysis. For 
each CpG site, case group versus control group means were compared using independent samples t-tests. 
Afterwards, t-test p-values were false discovery rate (FDR) corrected using the Benjamini-Hochberg (BH) 
approach32. Due to the exploratory nature of these analyses, unadjusted p values are presented first, followed 
TSS
cg12484332	
Chr17:	
1,443,819
cg00997378	
Chr17:	
1,444,260
cg08713711	
Chr17:	
1,444,333
cg13723431	
Chr17:	
1,444,395
cg15212349	
Chr5:	
1,444,852
cg27348223	
Chr5:	
1444878
cg26205131	
Chr5:	
1445354
cg045985
17	Chr5:	
1445542
cg12882697	
Chr5:	
1,445,549
cg04210284	
Chr5:	
1,445,561
cg27037018	
Chr5:	
1,445,567
CpG	Island	(1970bp)
Exon	1	(82bp)
Rat	Slc6a3	CpG1-10
cg17306747	
Chr5:	
1,446,165
cg17306747	
Chr5:	1,446,165
cg14502484	
Chr5:	
1,446,208
cg1670395
6	Chr5:	
1,446,217
cg1320275
1	Chr5:	
1,446,443
cg16180821	
Chr5:	1,446,969
Figure 3. SLC6A3 Mayo and DNHS CpG Methylation Probe Locations  
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by FDR-corrected results. Standard error of the mean (SEM) was calculated and included as error bars in the 
figures. In addition, Pearson correlation analyses were performed between mPFC and whole blood methylation 
values within each gene, within each case or control group. P values, and correlation coefficients are presented. 
Lifetime Major Depressive Disorder, Peripheral Methylation and Expression in the DNHS 
DNHS Sample. The Detroit Neighborhood Health Study (DNHS) is a longitudinal epidemiological study of 
adults older than 18 years old from Detroit, Michigan26,27. The DNHS study was performed in five waves; 
however, all measures relevant to the current study were gathered in wave 2. One participant per household 
was randomly selected from a total pool of 1547 households. Structured telephone interviews were conducted 
for each consenting participants, and included assessments of demographic (age, biological sex, self-reported 
race), socio-economic (educational attainment, household income), and psychiatric symptoms, including 
lifetime MDD according to DSM-IV criteria26.  A subset of DNHS participants provided blood samples via 
venipuncture (VP) through clinical in-home visits, at which time medication use was also recorded. From these 
VP blood draws, DNA was isolated from whole blood using the Qiagen QIAamp DNA Mini Kit (Catalogue 
No. 51306), and total RNA was isolated using the Ambion Leukolock kit (Catalogue No AM1923, Ambion, 
Foster City, CA). 
Methylation Microarray Analyses. 1ug of the whole blood isolated genomic DNA from 192 DNHS samples 
was subjected to BSC using the Zymo EZ-96 DNA Methylation Kit (Catalogue No. D5003, Zymo, Irvine, CA) 
and applied to the Illumina HumanMethylation450 (450k) BeadChip Kit (Catalogue No. WG-314-1002, 
Illumina, San Diego, CA), which measures methylation at more than 485,000 CpG sites per sample at single 
nucleotide resolution. Raw output from the 450k microarray was background corrected using the Illumina 
GenomeStudio Software and exported for additional analyses in the R programming language (version 3.2.4). 
DNA methylation measurements are represented by beta values, with 0 representing a completely 
unmethylated locus and 1 representing a completely methylated locus. Using the CpGAssoc package, the beta 
values matrix was subjected to quality control33. CpG sites were removed where the proportion of missing 
values across all samples exceeded 10%, and where the detection p-value was less than 0.001. Cross-
hybridizing probes and CpG sites near known single nucleotide polymorphisms34 were filtered out using the 
wateRmelon package in R35. Beta mixture quantile (BMIQ) normalization by subject was then implemented to 
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correct for probe type bias36. Then, principle component analysis (PCA) was performed on the beta values 
matrix to identify significant associations between technical artifacts/demographic measures and variability 
throughout the data. The identified chip and position technical artifacts were then corrected for while 
preserving the effects of biological sex and lifetime MDD status using ComBAT in R37, as implemented in the 
SVA package38.  After ComBAT, PCA was again performed to confirm chip and position technical artifact 
corrections. After the aforementioned background correction, quality control, filtering, normalization, and 
technical artifact correction, beta values from CpG sites near SLC6A4 and SLC6A3 TSS/CGI (Tables 2, 3) 
were extracted for each participant and compiled.  
 
 
Table 2. Illumina HumanMethylation450k BeadChip probes mapping to SLC6A4. 
Illumina ID Genome Build Chromosome
Probe 
Location
UCSC Gene 
Name
UCSC Gene 
Accession 
Number
UCSC Gene 
Functional Region UCSC Associated CGI
cg01330016 37/hg19 17 28549806 SLC6A4 NM_001045 5'UTR
cg26126367 37/hg19 17 28559497 SLC6A4 NM_001045 5'UTR chr17:28562387-28563186
cg05951817 37/hg19 17 28562142 SLC6A4 NM_001045 5'UTR chr17:28562387-28563186
cg22584138 37/hg19 17 28562220 SLC6A4 NM_001045 5'UTR chr17:28562387-28563186
cg03363743 37/hg19 17 28562474 SLC6A4 NM_001045 5'UTR chr17:28562387-28563186
cg14692377 37/hg19 17 28562685 SLC6A4 NM_001045 1stExon;5'UTR chr17:28562387-28563186
cg05016953 37/hg19 17 28562813 SLC6A4 NM_001045 1stExon;5'UTR chr17:28562387-28563186
cg25725890 37/hg19 17 28563054 SLC6A4 NM_001045 TSS200 chr17:28562387-28563186
cg26741280 37/hg19 17 28563089 SLC6A4 NM_001045 TSS200 chr17:28562387-28563186
cg10901968 37/hg19 17 28563108 SLC6A4 NM_001045 TSS200 chr17:28562387-28563186
cg27569822 37/hg19 17 28563119 SLC6A4 NM_001045 TSS200 chr17:28562387-28563186
cg18584905 37/hg19 17 28563300 SLC6A4 NM_001045 TSS1500 chr17:28562387-28563186
Illumina ID Genome Build Chromosome
Probe 
Location
UCSC Gene 
Name
UCSC Gene 
Accession 
Number
UCSC Gene 
Functional 
Region
UCSC Associated CGI
cg12484332 37/hg19 5 1443819 SLC6A3 NM_001044 5'UTR chr5:1444259-1444463
cg00997378 37/hg19 5 1444260 SLC6A3 NM_001044 5'UTR chr5:1444259-1444463
cg08713711 37/hg19 5 1444333 SLC6A3 NM_001044 5'UTR chr5:1444259-1444463
cg13723431 37/hg19 5 1444395 SLC6A3 NM_001044 5'UTR chr5:1444259-1444463
cg15212349 37/hg19 5 1444852 SLC6A3 NM_001044 5'UTR chr5:1444678-1446648
cg26205131 37/hg19 5 1444878 SLC6A3 NM_001044 5'UTR chr5:1444678-1446648
cg27348223 37/hg19 5 1445354 SLC6A3 NM_001044 5'UTR chr5:1444678-1446648
cg04598517 37/hg19 5 1445542 SLC6A3 NM_001044 5'UTR;1stExon chr5:1444678-1446648
cg12882697 37/hg19 5 1445549 SLC6A3 NM_001044 TSS200 chr5:1444678-1446648
cg04210284 37/hg19 5 1445561 SLC6A3 NM_001044 TSS200 chr5:1444678-1446648
cg27037018 37/hg19 5 1445567 SLC6A3 NM_001044 TSS200 chr5:1444678-1446648
cg05030481 37/hg19 5 1445593 SLC6A3 NM_001044 TSS200 chr5:1444678-1446648
cg17306747 37/hg19 5 1446165 SLC6A3 NM_001044 TSS1500 chr5:1444678-1446648
cg14502484 37/hg19 5 1446208 SLC6A3 NM_001044 TSS1500 chr5:1444678-1446648
cg16703956 37/hg19 5 1446217 SLC6A3 NM_001044 TSS1500 chr5:1444678-1446648
cg13202751 37/hg19 5 1446443 SLC6A3 NM_001044 TSS1500 chr5:1444678-1446648
cg16180821 37/hg19 5 1446969 SLC6A3 NM_001044 TSS1500 chr5:1444678-1446648
Table 3. Illumina HumanMethylation450k BeadChip probes mapping to SLC6A3. 
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Expression Microarray Analyses. Total RNA was applied to the Illumina HumanHT-12 v4 Expression 
BeadChip (HT-12)39, which assesses mRNA expression at > 47,000 transcripts in the human genome. Raw 
output from the HT-12 microarray (n = 129) was background corrected using the Illumina GenomeStudio 
Suite. Expression intensity values derived from HT-12 are continuous variables, which were log transformed 
for normality and variance stability, then filtered to remove probes with low intensity or that exhibited cross-
hybridization34. Then, PCA was performed on the expression intensity values matrix to identify significant 
associations between technical artifacts/demographic measures and variability throughout the data. The 
identified chip technical artifact was then corrected for while preserving the effects of biological sex and 
lifetime MDD status using ComBAT37 in R, and implemented in the SVA package38. PCA was again 
performed to confirm chip technical artifact correction. After the aforementioned processing steps, mRNA 
expression intensity values for probes mapping to SLC6A4 and SLC6A3 (Tables 4, 5) were extracted.  
In addition to demographic, methylation, and expression measures taken for each participant, cell type 
heterogeneity40 and ancestry41 principle components (PCs) were derived for each participant, based on DNA 
methylation measurements, for inclusion as covariates in downstream analyses. Cell heterogeneity PCs were 
included in order to correct for cell type specific methylation and expression profiles, whereas ancestry PCs 
were included to correct for potential population stratification. A total of 104 wave 2 subjects were included in 
the methylation- and expression-based DNHS analyses.  
Statistical Analyses. Main effect regression models were employed to establish the relationship between 
predictors of interest and outcomes of interest. Utilizing multivariate linear regression, model one used CpG 
methylation of 12 SLC6A4 450k probes nearest to the TSS from human blood as predictors of HT-12 mRNA 
expression of SLC6A4 (ILMN_1683694) from human blood (Figure 1, Relationship A). Included in the model 
Illumina	Probe	ID Chromosome Probe	Location UCSC	Gene	Name UCSC	Gene	Accession	Number Protein_ProductILMN_1683694 17 25549322-25549371 SLC6A4 NM_001045.3 NP_001036.1
Table 4. Illumina HumanHT-12 v4 Expression BeadChip probes mapping to SLC6A4. 
Illumina Probe ID Chromosome Probe Location UCSC Gene Name
UCSC Gene 
Accession 
Number
Protein Product
ILMN_23614 5 1446076-1446125 SLC6A3 NM_001044.2 NP_001035.1
Table 5. Illumina HumanHT-12 v4 Expression BeadChip probes mapping to SLC6A3. 
	 12	
as covariates were: participant age at time of blood draw, biological sex, ancestry principle components (PCs 
2, 3, and 4), cell type heterogeneity estimates (CD8T, CD4T, NK, Bcell, and monocytes), and antidepressant 
medication status. These covariates were also included in all regression models to follow. Note, CpG 
methylation of the 17 SLC6A3 450k probes from human blood were not used with this model because the HT-
12 mRNA expression probe mapping to SLC6A3 was filtered out during initial processing steps. Next, utilizing 
logistic regression, model two used HT-12 mRNA expression of SLC6A4 (ILMN_1683694) from human 
blood as the predictor of lifetime MDD diagnosis status, retaining the same covariates as the previous model 
(Figure 1, Relationship B). Again utilizing logic regression, model three used CpG methylation of 12 SLC6A4 
450k probes nearest to the TSS from human blood as the predictor of lifetime MDD diagnosis status, retaining 
the same covariates as the previous model (Figure 1, Relationship C). Additionally, using the same model 
design, CpG methylation of 17 SLC6A3 450k probes nearest to the TSS from human blood served as the 
predictor of lifetime MDD diagnosis status, retaining the same covariates as the previous model (Figure 1, 
Relationship C). 
Supplementary analyses of publically available datasets  
In order to highlight brain CpG methylation associations with lifetime MDD diagnosis status, 
supplementary analyses were performed using the National Center for Biotechnology Information (NCBI) 
Gene Expression Omnibus (GEO). A publically available dataset was located in which DNA methylation was 
profiled for both neuronal and glial nuclei[42]. These profiles were obtained from human post-mortem frontal 
cortex of “healthy” control subjects (n = 29) and age/sex matched major depression case subjects (n = 29) 
using the Illumina HumanMethylation450 (450k) Beadchip (GEO Accession No. GSE41826). According to 
study information, cell types were sorted using fluorescent activated cell sorting (FACS). Subsequently, 
genomic DNA was isolated from neuronal nuclei, bisulfite converted, fragmented, and hybridized to the 450k 
Beadchip. Raw output was background corrected using GenomeStudio, and beta values were normalized. 450k 
beta values, age, sex, race, MDD status, post-mortem interval in hours (PMI), and suicide completion status 
were extracted from GEO. Afterwards, cross-hybridizing probes and CpG sites near known single nucleotide 
polymorphisms[34] were filtered out[35]. Then, PCA was performed on the beta value matrix to identify 
significant associations between technical artifacts/demographic measures and variability throughout the data. 
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The known chip and position technical artifacts were then corrected. After the aforementioned background 
correction, normalization, and technical artifact correction, beta values from CpG sites near the SLC6A4 
TSS/CGI (Table 2) were extracted for each participant and compiled. The data were analyzed using the R 
programming language. Utilizing logic regression, model four used CpG methylation of the 12 SLC6A4 450k 
probes nearest to the TSS from human frontal cortex neurons as the predictor of lifetime MDD diagnosis status 
(Figure 1, Relationship C). Suicide completion status, biological sex, self-reported race, age at time of death, 
and post-mortem interval were included in this model as covariates. Afterwards, FDR correction using the BH 
method was employed.  
In order to highlight intra-subject brain and blood CpG methylation correlations in humans, 
supplementary analyses were performed using the Blood Brain DNA Methylation Comparison Tool available 
at http://epigenetics.iop.kcl.ac.uk/bloodbrain28. Specifically, we investigated the CpG methylation of “healthy” 
control subjects (n=75) in whole blood as well as PFC. Pairwise correlation analysis for the methylation of 
each Illumina 450k Beadchip probe mapping nearest to the TSS of the SLC6A4 (Table 2) and SLC6A3 (Table 
3) genes was performed between blood and PFC. Comparison results were not subjected to BH FDR 
corrections. 
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Chapter 3: Results 
ACTH-Induced Treatment-Resistant Depression Model in the Rat 
 Slc6a3 Independent samples t-tests of CpG methylation in mPFC tissue showed significant differences 
between cases and controls at CpG1-9 individually (p < 0.050, cases > controls in all tests). The CpG10 
independent samples t-tests comparison showed no significant difference (Table 6). BH FDR correction 
rendered only CpG6 non-significant. In whole blood, independent samples t-tests showed a significant 
difference between cases and controls at CpG1, however in a direction opposite to that observed in mPFC (p = 
0.041, control > case) (Table 7). BH FDR correction rendered this comparison non-significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Rat Slc6a3 mPFC methylation descriptive statistics, independent samples t-test p-values, and BH FDR correction. 
Control Mean ± SEM Case Mean ± SEM t-test p value BH FDR Correction
CpG1 4.137 ± 0.238 5.645 ± 0.273 0.001 sig.
CpG2 7.016 ± 0.802 11.441 ± 1.267 0.014 sig.
CpG3 4.944 ± 0.523 6.762 ± 0.376 0.011 sig.
CpG4 4.976 ± 0.568 8.565 ± 0.977 0.009 sig.
CpG5 2.076 ± 0.309 3.398 ± 0.308 0.009 sig.
CpG6 4.604 ± 0.571 6.845 ± 0.846 0.047 ns.
CpG7 5.427 ± 0.635 8.935 ± 0.944 0.008 sig.
CpG8 4.881 ± 0.419 6.695 ± 0.572 0.029 sig.
CpG9 2.719 ± 0.239 3.640 ± 0.259 0.022 sig.
CpG10 2.919 ± 0.239 3.417 ± 0.201 0.126 ns.
1-10 CpG AVG 4.313 ± 0.205 6.267 ± 0.299 0.0000002 sig.
Table 7. Rat Slc6a3 blood methylation descriptive statistics, independent samples t-test p-values, and BH FDR correction. 
Control Mean ± SEM Case Mean ± SEM t-test p value BH FDR Correction
CpG1 5.401 ± 0.422 4.192 ± 0.359 0.041 ns.
CpG2 8.252 ± 0.970 8.997 ± 1.012 0.604 ns.
CpG3 7.691 ± 0.861 7.662 ± 0.794 0.981 ns.
CpG4 7.102 ± 0.973 6.921 ± 1.188 0.908 ns.
CpG5 3.086 ± 0.365 3.202 ± 0.506 0.864 ns.
CpG6 5.998 ± 0.765 5.458 ± 0.657 0.597 ns.
CpG7 6.946 ± 0.646 7.092 ± 0.885 0.895 ns.
CpG8 6.391 ± 0.460 5.620 ± 0.696 0.366 ns.
CpG9 3.186 ± 0.247 4.434 ± 0.625 0.083 ns.
CpG10 3.421 ± 0.296 3.040 ± 0.284 0.365 ns.
1-10 CpG AVG 5.702 ± 0.265 5.572 ± 0.282 0.738 ns. 
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When comparing average case and control group CpG methylation across all 10 Slc6a3 CpG sites in mPFC, 
the case group showed a significantly higher level of CpG methylation compared to the control group (p = 
2.1x10-6) (Figure 4). This aggregate comparison remained significant after BH FDR correction. When 
comparing average case and control group CpG methylation across all 10 Slc6a3 CpG sites in whole blood, no 
significant difference was detected (p > 0.05) (Figure 5).  
 
 
 
 
 
 
 
 
Slc6a4 mPFC methylation independent samples t-tests showed no significant differences between case 
and control group means at any measured CpG sites (Table 8). In whole blood, independent samples t-tests 
showed a significant difference between case and control group means at CpG19 (p = 0.008, case > control) 
(Table 9).  However, this comparison did not survive BH FDR correction as significant. 
 
 
 
 
 
 
 
 
 CpG 1 - 10 
 
Figure 5. Rat whole blood Slc6a3 CpG Methylation 
aggregate comparison of CpG 1-10 (p > 0.05). 
       CpG 1 - 10 
 
Figure 4. Rat mPFC Slc6a3 CpG Methylation aggregate 
comparison of CpG 1-10 (* p < 0.000005). 
Table 8. Rat Slc6a4 mPFC methylation descriptive statistics, independent samples t-test p-values, and BH FDR correction. 
Control Mean ± SEM Case Mean ± SEM t-test p value BH FDR Correction
CpG12 3.278 ± 0.240 2.818 ± 0.164 0.121 ns.
CpG13 1.556 ± 0.156 1.856 ± 0.207 0.284 ns.
CpG14 1.981 ± 0.227 2.271 ± 0.123 0.253 ns.
CpG15 2.031 ± 0.503 1.916 ± 0.168 0.815 ns.
CpG16 4.537 ± 0.340 4.173 ± 0.220 0.361 ns.
CpG17 3.944 ± 0.294 3.852 ± 0.200 0.792 ns.
CpG18 2.828 ± 0.416 2.833 ± 0.132 0.988 ns.
CpG19 2.958 ± 0.285 2.946 ± 0.283 0.978 ns.
CpG20 2.869 ± 0.220 2.483 ± 0.144 0.143 ns.
CpG21 2.739 ± 0.258 3.022 ± 0.123 0.295 ns.
CpG22 2.503 ± 0.068 2.719 ± 0.126 0.193 ns.
CpG23 2.131 ± 0.449 1.56 ± 0.105 0.141 ns.
12-23 CpG AVG 2.845 ± 0.119 2.759 ± 0.083 0.539 ns.
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When comparing average case and control group CpG methylation across all 12 Slc6a4 CpG sites in mPFC 
(Figure 6) and in whole blood (Figure 7), no significant differences were detected (p > 0.05).		
Pearson correlational analyses between mPFC and whole blood methylation values were performed 
for each gene on a per CpG site basis, within each case and control group. No significant relationship was 
observed between mPFC and whole blood CpG methylation values at any site in the Slc6a4 gene in either the 
case or control group. In contrast, within Slc6a3, significant correlations were observed for CpG methylation 
Table 9. Rat Slc6a4 blood methylation descriptive statistics, independent samples t-test p-values, and BH FDR correction. 
Control Mean ± SEM Case Mean ± SEM t-test p value BH FDR correction
CpG12 3.633 ± 0.3050 3.99 ± 0.3890 0.474 ns.
CpG13 3.888 ± 0.3600 3.369 ± 0.4360 0.370 ns.
CpG14 3.25 ± 0.2170 2.962 ± 0.3170 0.472 ns.
CpG15 2.855 ± 0.4340 2.317 ± 0.2090 0.265 ns.
CpG16 5.67 ± 0.4730 5.53 ± 0.3780 0.820 ns.
CpG17 4.952 ± 0.3950 4.95 ± 0.3180 0.998 ns.
CpG18 3.049 ± 0.1940 3.593 ± 0.4220 0.257 ns.
CpG19 3.092 ± 0.2470 4.403 ± 0.3520 0.008 ns.
CpG20 3.493 ± 0.2080 3.992 ± 0.4150 0.282 ns.
CpG21 3.703 ± 0.1920 3.858 ± 0.3740 0.727 ns.
CpG22 3.17 ± 0.2660 3.898 ± 0.5430 0.241 ns.
CpG23 2.757 ± 0.3120 3.316 ± 0.3780 0.265 ns.
12-23 CpG AVG 3.631 ± 0.1160 3.829 ± 0.1300 0.258 ns.
Figure 6. Rat mPFC Slc6a4 CpG Methylation aggregate 
comparison of CpG 12-23 (p > 0.05). 
Figure 7. Rat whole blood Slc6a4 CpG Methylation aggregate 
comparison of CpG 12-23 (p > 0.05). 
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values between mPFC and whole blood in CpG 2 (p = 0.002, r = 0.987, df = 3) and CpG 5 (p = 0.001, r = 
0.841, df = 8) in the case group (Table 10); and in the control group for CpG methylation values between 
mPFC and whole blood in CpG 3 (p = 0.023, r = 0.927, df = 3) (Table 10). Although both significant 
correlations in the case group survived BH FDR correction, the correlation in the control group did not. 
 
 
 
 
 
 
 
Lifetime Major Depressive Disorder, Peripheral Methylation and Expression in the DNHS 
 Model one used CpG methylation of the 12 SLC6A4 450k probes from human blood as predictor 
variables and HT-12 expression of SLC6A4 in human blood as the response variable. Cg05951817 methylation 
was significantly associated with ILMN_1683694 expression (p = 0.004) (Table 11). Additionally, 
cg10901968 methylation was shown to be significantly associated with ILMN_1683694 expression (p = 0.025) 
(Table 12). However, BH FDR correction attenuated these results to non-significance. 
 
  
 
 
 
 
 
 
 
Case Group mPFC v. Whole Blood BH FDR Correction Control Group mPFC v. Whole Blood BH FDR Correction
CpG1 ns. ns. ns. ns.
CpG2 p = 0.002, r = 0.987, df = 3 sig. ns. ns.
CpG3 ns. ns. p = 0.023, r = 0.927, df = 3 ns.
CpG4 ns. ns. ns. ns.
CpG5 p = 0.001, r = 0.841, df = 8 sig. ns. ns.
CpG6 ns. ns. ns. ns.
CpG7 ns. ns. ns. ns.
CpG8 ns. ns. ns. ns.
CpG9 ns. ns. ns. ns.
CpG10 ns. ns. ns. ns.
Table 10. Rat Slc6a3 mPFC v. whole blood Pearson correlation analysis. 
Table 11. Association between cg05951817 
methylation and ILMN_1683694 mRNA expression. 
Table 12. Association between cg10901968 
methylation and ILMN_1683694 mRNA expression. 
beta t value p value                  beta t value p value    
Intercept     5.771 23.215 <2e-16 * Intercept     6.065 28.738 <2e-16 *
cg05951817      0.628 2.929 0.004 * cg10901968      4.498 2.280 0.025 *
Age             0.000 0.683 0.496 Age             0.001 1.294 0.199
female2         0.022 0.722 0.472 female2        -0.004 -0.167 0.868
Comp.2         -0.285 -1.091 0.278 Comp.2         -0.335 -1.259 0.211
Comp.3         -0.749 -1.168 0.245 Comp.3         -1.027 -1.583 0.117
Comp.4          0.135 0.591 0.556 Comp.4         0.000 -0.001 0.999
CD8T            0.184 0.355 0.723 CD8T            0.367 0.700 0.486
CD4T            0.111 0.318 0.751 CD4T            0.071 0.200 0.842
NK              0.782 1.644 0.103 NK             0.676 1.397 0.166
Bcell           0.697 1.649 0.102 Bcell           0.874 2.000 0.048 *
Mono           -0.334 -0.641 0.523 Mono           -0.045 -0.088 0.930
Antidepressant  0.017 0.454 0.651 Antidepressant  0.013 0.336 0.738
 
Significance Codes:  *p < 0.05, #p< 0.10 Significance Codes:  *p < 0.05, #p< 0.10
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Next, model two used HT-12 expression of 
SLC6A4 in human blood as the predictor, and lifetime 
MDD diagnosis status as the outcome variable. 
ILMN_1683694 mRNA expression approached 
significance as a predictor of lifetime MDD diagnosis 
status (p = 0.076) (Table 13). In this model, age (p = 
0.012) and antidepressant medication status (p = 0.003) 
were also shown to be significantly associated with 
lifetime MDD diagnosis status.  
Finally, in model three, CpG methylation of the 12 SLC6A4 450k probes from human blood were 
used as predictors of lifetime MDD. Cg01330016 methylation was significantly associated with lifetime MDD 
diagnosis status (p = 0.008) (Table 14). Cg18584905 methylation was also significantly associated with 
lifetime MDD diagnosis status (p = 0.015) (Table 15). It should be noted, CpG methylation of the 17 SLC6A3 
450k probes from human blood were used as predictors of the lifetime MDD diagnosis outcome, and these 
analyses rendered no significant results. BH FDR correction attenuated the two significant results to non-
significance. 
 
 
 
 
 
 
 
 
 
 
 
beta z value p value   
Intercept     -20.148 -1.445 0.149
ILMN_1683694     3.867 1.775 0.076 #
Age              -0.058 -2.518 0.012 *
female2          -0.528 -0.868 0.385
Comp.2           -3.357 -0.638 0.523
Comp.3           19.413 1.429 0.153
Comp.4            0.483 0.102 0.919
CD8T            -15.158 -1.419 0.156
CD4T             -3.810 -0.521 0.602
NK               -9.113 -0.878 0.380
Bcell             5.263 0.621 0.535
Mono             15.321 1.505 0.132
Antidepressant2  -2.224 -2.962 0.003 *
 
Significance Codes:  *p < 0.05, #p< 0.10
Table 13. Association between ILMN_1683694 mRNA 
expression and lifetime MDD diagnosis status.  
Table 14. Association between cg01330016 
methylation and lifetime MDD diagnosis status.  
Table 15. Association between cg18584905 
methylation and lifetime MDD diagnosis status.  
beta z value p value  beta z value p value
Intercept     -61.750 -2.466 0.014 * Intercept       8.759 2.055 0.040 *
cg01330016       68.796 2.624 0.008 * cg18584905      -47.773 -2.440 0.015 *
Age              -0.052 -2.139 0.032 * Age              -0.056 -2.395 0.017 *
female2          -0.334 -0.530 0.596 female2          -0.940 -1.396 0.162
Comp.2           -7.140 -1.290 0.197 Comp.2           -2.935 -0.544 0.586
Comp.3           18.352 1.422 0.154 Comp.3           18.981 1.420 0.155
Comp.4            3.750 0.729 0.465 Comp.4            0.575 0.121 0.903
CD8T            -15.401 -1.415 0.157 CD8T             -8.505 -0.808 0.419
CD4T             -0.970 -0.133 0.894 CD4T              1.262 0.167 0.867
NK               -4.646 -0.485 0.628 NK               -0.576 -0.055 0.956
Bcell             9.579 1.124 0.260 Bcell             9.861 1.102 0.270
Mono             20.396 1.863 0.063 Mono             16.633 1.607 0.108
Antidepressant2  -1.953 -2.729 0.006 * Antidepressant2  -2.327 -3.090 0.002 *
  
Significance Codes:  *p < 0.05, #p< 0.10 Significance Codes:  *p < 0.05, #p< 0.10
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Supplementary analyses of publically available datasets 
In model four, logistic regression was implemented using the Guintivano 450k neuron CpG 
methylation dataset. The 12 SLC6A4 450k methylation probes were used as predictors of the lifetime MDD 
diagnosis status response variable (Table 2). FDR uncorrected results from this main effects model are as 
follows. Cg27569822 methylation was shown to approach nominally significant association with lifetime 
MDD diagnosis status (p = 0.053). In this model, suicide completion status was shown to be significantly 
associated with lifetime MDD diagnosis status (p = 0.0001) along with age (p = 0.0353) (Table 16). 
Importantly, FDR correction of these results using the BH 
method rendered no remaining significant results. 
Our final analyses utilized the publically available 
Blood Brain DNA Methylation Comparison Tool28 to highlight 
intra-subject brain and blood CpG methylation correlations. 
Using this tool, the blood derived CpG methylation value of 
each probe (Tables 2, 3) was compared to the CpG methylation 
values of that same probe, derived from PFC. Out of the 12 450k probes mapping to the SLC6A4 genic region, 
2 probes’ methylation values were shown to be significantly correlated between blood and PFC. Cg14692377 
blood and PFC exhibited the strongest positive correlation amongst any comparison of SLC6A4 between 
tissues (p = 0.001, r = 0.367, df > 71) (Table 17). Out of the 17 450k probes mapping to the SLC6A3 genic 
region, 5 probes’ methylation values were significantly correlated between blood and PFC. The strongest 
correlation was that of cg16180821 (p = 0.004, r = 0.329, 
df > 71). (Table 18).  
 
 
                 beta z value p value    
Intercept -17.07 -2.252 0.024 *
cg27569822      174.42 1.936 0.053 #
suicide_status1   4.972 3.858 0.001 *
sex2              1.226 1.269 0.204
race2            -0.182 -0.18 0.857
age               0.063 2.104 0.035 *
pmi              -0.028 -0.394 0.693
Significance Codes: *p <0.05, #p < 0.10
Table 16. Association between cg27569822 frontal 
cortex neuronal methylation and lifetime MDD 
diagnosis status 
 
Table 17. Hannon et al., 2015 Human Blood Brain CpG 
Methylation Correlation Analysis (SLC6A4 probes, df > 
71). Significant intra-subject correlations between blood 
and PFC tissues. 
 
Illumina 450k 
Probe Blood v. PFC
cg14692377 p = 0.001,  r = 0.367
cg05016953 p = 0.047,  r =0.232
Table 18. Hannon et al., 2015 Human Blood Brain CpG 
Methylation Correlation Analysis (SLC6A3 probes, df > 
71). Significant intra-subject correlations between blood 
and PFC tissues. 
 
Illumina 450k 
Probe Blood v. PFC
cg08713711 p = 0.02, r = 0.262
cg27348223 p = 0.045, r = 0.234
cg17306747 p = 0.009,  r = 0.301
cg13202751 p = 0.040, r = 0.239
cg16180821 p = 0.004, r = 0.329
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Chapter 4: Discussion  
Identification of salient peripheral biomarkers of TRD and MDD is critically important due to the 
great burden these disorders carry, and because of the inability to access etiological CNS tissues in living 
humans. Such biomarkers can help to elucidate the neurobiological underpinnings of treatment resistance in 
certain patients, as well as provide a biological indicator of disease state rather than a subjective symptom 
indicator as frequently relied upon in clinical settings. Methylation of a CpG dinucleotide is regarded as a 
stable epigenetically induced mark, which is often associated with an increase or decrease in transcription of 
associated mRNA transcripts42 and for this reason is the main focus of the current study.   
Using an ACTH-induced TRD model in the rat, we identified differentially methylated CpG sites 
between our case and control groups, partially confirming the initially posed hypothesis that ACTH-exposed 
animals would exhibit significantly differential CpG methylation in the regions near the TSS of Slc6a3 and 
Slc6a4 genes in mPFC tissue and whole blood, compared to control group animals. Of particular interest 
within Slc6a3, CpG1 exhibited a significant difference between cases and controls in mPFC, and importantly 
in whole blood as well. However, in mPFC tissue, the case group had a higher mean methylation value than 
the control group, whereas the opposite direction of effect was observed in blood. Slc6a4 analyses also 
indicated a significant difference between case and control groups at CpG19 in blood, where the case group 
exhibited higher methylation values than the control group. Furthermore, Slc6a3 exhibited significant positive 
correlations between methylation levels detected in brain and blood, within both the case and control groups. 
Interestingly, Slc6a4 exhibited no significant correlations between tissues within either the case group of the 
control group. Results from correlation analyses provided a modest degree of evidence towards confirmation 
of the rat intra-subject blood brain correlation hypothesis. .  
Taken together, results from our ACTH-induced TRD model in the rat indicate that CpG methylation 
alterations in the promoter region of Slc6a3 occurring in the brain and blood are a strong candidate for 
functional relevance to the pathology of TRD. Although we were unable to test this in the current study, a 
mechanism by which CpG methylation is related to the TRD phenotype likely involves alteration to mRNA 
expression of the downstream Slc6a3 gene. Based on current genomic understanding, an increase in CpG 
methylation of the promoter region is likely to be associated with decreased mRNA expression due to steric 
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exclusion of polymerases and transcription factors22. This decrease in mRNA expression of the Slc6a3 
transcript could then result in a decrease of its corresponding protein, the dopamine reuptake transporter. With 
less of this protein available for embedding into the pre-synaptic neuron’s terminal membrane, more DA 
would remain in the synaptic cleft for longer periods of time, increasing its utilization by the post-synaptic 
neuron. However, accounting for the potential biological effect of chronic ACTH exposure and Slc6a3 CpG 
methylation in both the CNS and periphery is more challenging, and currently the role of Slc6a3 mRNA 
expression in the blood is not well characterized. Nevertheless, our findings suggest that CpG1 of Slc6a3 in the 
blood represents the most salient peripheral biomarker of TRD, due to its corresponding association with TRD 
detected in mPFC as well (albeit in opposite directions). Additionally, results indicate that CpG methylation 
alterations occurring in the first exon of Slc6a4 in the blood also represent a potential peripheral biomarker of 
TRD in the current model, although evidence for this conclusion is less robust because CpG19 is not 
significant in mPFC. The juxtaposition of results pertaining to both Slc6a3 and Slc6a4 in the ACTH-induced 
rat model of TRD are of great significance. It is not surprising to see no alteration of Slc6a4 methylation in the 
mPFC in TRD, as one of the most common methods of treatment for initial MDD is by way of SSRI’s. 
Ineffective treatment with SSRI’s implies the targeted system may not be aberrantly regulated, as potentially in 
the case of the ACTH-induced rat model of TRD. On the other hand, the ineffective initial treatment of SSRI’s 
logically suggests alternative disrupted pathologies, and evidence from the current study points to the aberrant 
regulation of Slc6a3. 
After investigating the relationship between peripheral and CNS tissue methylation in the rodent 
model of TRD to index CNS differential methylation with peripheral methylation, peripheral methylation and 
expression measures were investigated in human blood in an attempt to characterize potential peripheral 
biomarkers characteristic of MDD, and to potentially predict what is occurring in the brain. Using peripheral 
genome-wide methylation and expression data derived from the DNHS to investigate lifetime MDD in 
humans, the current study highlighted that two 450k probes mapping near the TSS of SLC6A4 (cg05951817 
and cg10901968) were significantly associated with mRNA expression of the SLC6A4 transcript 
(ILMN_1683694).  Additionally, the SLC6A4 mRNA expression probe approached a significant association 
with lifetime MDD, and two 450k probes (cg01330016 and cg 18584905) were significantly associated with 
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lifetime MDD. Hypotheses pertaining to this portion of the current study predicted significant associations 
between: SLC6A4 450k probe methylation and SLC6A4 HT12 probe mRNA expression, SLC6A4 HT12 probe 
mRNA expression and lifetime MDD diagnosis, and SLC6A4 450k probe methylation and lifetime MDD 
diagnosis. Evidence exists in favor of all three hypotheses, and provides a potentially mechanistic explanation 
to the model presented in Figure 1. Cg05951817 is located in the first intron of the gene, whereas cg10901968 
is located in the promoter region of the gene about 70bp upstream of the TSS in the same CGI (Figure 2). 
Previous work from our lab showed that a differentially methylated intronic SLC6A4 CpG site modified the 
association between number of traumatic events and PTSD diagnosis within the DNHS cohort43. Additionally, 
differential intronic CpG methylation at the cg22584138 locus has previously been associated with silencing of 
mRNA transcription44, and the role of non-coding intronic DNA is becoming more salient in regards to 
transcriptional regulation45. On the other hand, cg10901968 has been shown to be a significant predictor of 
depressive symptoms in African American women46, and differential blood-derived CpG methylation of sites 
in this region have been significantly associated with in vivo measures of human brain 5HT synthesis47, 
pointing to potential functional significance of both CpG sites and their respective methylation values in 
humans. Furthermore, our nominally significant association between mRNA expression of blood SLC6A4 
transcript and lifetime MDD status provides evidence for the potentially functional effect of differential 
methylation of CpG sites within and near the SLC6A4 gene. Transcription of this gene is regulated by both 
genetic and epigenetic factors, and CpG methylation is well documented to be one of them. It is therefore 
possible that differential CpG methylation of SLC6A4 in the blood is related to differential SLC6A4 mRNA 
expression in the blood, and that these factors together are related to indicators of pathology of lifetime MDD. 
What further strengthens this argument are the significant associations between cg01330016 and cg18584905 
to lifetime MDD status. These CpG sites are located in intron one and the promoter region of SLC6A4 
respectively, the same functional regions as the CpG mRNA expression associations (Figure 2).   
 Overall, the second phase of the current study showed that in peripheral blood, CpG methylation and 
mRNA expression of SLC6A3 are not relevant as indicators of lifetime MDD pathology moving forward. On 
the other hand, it appears that SLC6A4 CpG methylation of the first intron and the promoter regions are of 
functional significance in regards to serving as an indicator of the disorder. The CpG sites are most likely sites 
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of transcriptional regulation, with the functional differences in indicators of pathology stemming directly from 
differential mRNA expression. Further inquiry is necessary. Note, no Illumina CpG methylation 450k probes 
near the TSS of SLC6A3 were significantly associated with lifetime MDD diagnosis, and the mRNA 
expression probe mapping to SLC6A3 was removed during quality control and pre-processing. Therefore, 
results pertaining to SLC6A3 indicate that although implicated in the neurological etiology of MDD, SLC6A3 
CpG methylation near the promoter region potentially plays no role as a biomarker of MDD as measured in the 
blood. 
The third portion of the current study hypothesized that frontal cortex neuronal CpG methylation of 
probes mapping to SLC6A4 would be significantly associated with lifetime MDD diagnosis status. Using a 
supplementary and publically available neuronal genome-wide methylation data set, one inter-subject CpG site 
methylation value was shown to approach significant association with lifetime MDD diagnosis status, and it 
did not survive FDR BH correction. This can be potentially attributed to a lack of comprehensive covariates 
included in regression modeling as well as small sample size. This null result lends no evidence to the initial 
hypothesis.  
The final portion of the current study hypothesized that CpG methylation of probes mapping to the 
human SLC6A3 and SLC6A4 gene would show significant correlations within subjects, between blood and 
PFC tissue. Using the publically available Blood Brain DNA Methylation Comparison Tool, 2 out of 12 
SLC6A4 intra-subject blood versus PFC correlation comparisons were shown to reach significance, and 5 out 
of 17 SLC6A3 intra-subject blood versus PFC correlation comparisons were shown to reach significance. All 
significant relationships were positive. The moderate quantity of significant correlation indicates that within 
subjects, brain and blood methylation levels are potentially related in mostly “healthy” subjects. This finding, 
along with the empirical findings from the research originating the DNA Methylation Comparison Tool28, 
lends moderate support to the idea that in some cases peripheral CpG methylation can be used as surrogate for 
CNS CpG methylation. 
  As in any study, limitations are present. However, these limitations present opportunities for 
improvement in regards to future directions. The first limitation of the ACTH-induced TRD animal model 
study is the use of an exclusively male sample of animals in the ACTH rodent study. Notable differences 
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between sexes in regards to TRD, MDD, and antidepressant efficacy have been widely reported48,49. In the 
future, a cohort of animals comprised of both male and female rodents would be ideal. The next limitation of 
mention is the lack of mRNA expression data for the candidate genes of interest in this study. Although CpG 
methylation has been shown to functionally alter mRNA expression in some scenarios, this cannot be assumed 
for any given CpG site without empirical validation. Additionally, mRNA expression data would provide 
further insight as to the pathology of ACTH-induced TRD. In this same line of thought, expression of other 
types of RNA (e.g. long non-coding RNA, micro RNA) could also be investigated in the future, as some have 
been shown to function in regulatory roles50. The next limitation to mention is that Slc6a3 and Slc6a4 were 
selected as candidate genes for the current study due to previous empirical findings and based on previous 
research. However, current trends in the field suggest the importance of polygenic investigation at many levels 
of biology. Ongoing international consortia are conducting genome-wide investigations of MDD that integrate 
DNA methylation, mRNA expression, and SNP data to further characterize the genomic basis of this disorder.  
Regarding the second portion of our study, one limitation of the DNHS study is the lack of validation 
of genome-wide methylation and expression data from the 450k and HT-12 platforms. Although these 
platforms are widely accepted and well regarded in the field, validation through bisulfite pyrosequencing and 
RT-PCR would strengthen our preliminary conclusions. One future direction is of special interest to the current 
study. Inclusion of human SLC6A4 5HTTLPR genotype would potentially strengthen the fit of the regression 
models that were employed, as genotype of this locus has been shown to significantly affect expression of the 
SLC6A4 mRNA transcript, and to be significantly associated with MDD diagnosis status21. Inclusion of these 
factors may increase the amount of variability explained by the model and, in doing so, help to increase 
understanding of the pathology involved in this disorder. Next, the neuronal Illumina 450k dataset utilized in 
the current study[42] included methylation values, age, sex, race, PMI, lifetime MDD diagnosis status, and 
suicide completion status from frontal cortex tissue of 29 “healthy” control subjects and 29 lifetime MDD 
diagnosis affirmative case subjects. Although the aforementioned covariates were included in the model, many 
potential covariates were not available for inclusion. Stratified ancestry principle components, antidepressant 
information, and comorbid disorder information would have strengthened the model, and could have explained 
more of the variability. Finally, although our supplementary analyses of human data using the Blood Brain 
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DNA Methylation Comparison Tool offered some insight as to the relationship between CpG methylation in 
blood versus PFC within a given subject, the ability to control for demographic and technical artifacts is not 
possible within the context of the publically available tool.  
In conclusion, the current study has preliminarily identified blood-derived, DNA-methylation based 
peripheral biomarkers of TRD in Slc6a3 at CpG1, and in Slc6a4 at CpG19. In humans, methylation of two 
CpG sites in the first intron and promoter region of SLC6A4 have also been identified preliminarily as 
peripheral biomarkers of MDD. Additionally, SLC6A4 mRNA expression in blood has also been identified 
preliminarily as a peripheral biomarker of MDD in humans. Furthermore, significant correlation analyses in 
both rat and human showed moderate concordance between blood and brain CpG methylation levels at select 
CpG sites in our two loci of interest. These potential peripheral biomarkers, identified in easily accessible 
tissues, offer the opportunity for biologically based diagnosis efforts of TRD or MDD, and give insight as to 
the potential underlying mechanisms of these disorders. However, efforts to elucidate additional peripheral 
biomarkers should continue to expand, as polygenic factors at multiple levels of physiology are likely more 
explanatory than candidate gene based research. 
 
 
 
 
 
 
 
 
 
 
 
	 26	
References 
1. Stetler, C., & Miller, G. E. (2011). Depression and hypothalamic-pituitary-adrenal activation: a quantitative 
summary of four decades of research. Psychosomatic medicine, 73(2), 114-126. 
2. American Psychiatric Association. (2013). DSM 5. American Psychiatric Association. 
3. Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., ... & Wang, P. S. (2003). 
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication 
(NCS-R). Jama, 289(23), 3095-3105. 
4. Melartin, T. K., Rytsala, H. J., Leskela, U. S., Lestela-Mielonen, P. S., Sokero, T. P., & Isometsa, E. T. 
(2002). Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in 
psychiatric care in the Vantaa Depression Study. Journal of Clinical Psychiatry, 63(2), 126-134. 
5. Lesage, A. D., Boyer, R., Grunberg, F., Vanier, C., Morissette, R., & Loyer, M. (1994). Suicide and mental 
disorders: a case-control study of young men. The American journal of psychiatry, 151(7), 1063. 
6. Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. (2004). Global burden of 
depressive disorders in the year 2000. The British journal of psychiatry, 184(5), 386-392. 
7. Frank, E., & Karp, J. (1993). Rush AJ. Efficacy of treatments for major depression. Psychopharmacol 
Bull, 29, 457-75. 
8. Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., ... & Shores-
Wilson, K. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care 
in STAR* D: implications for clinical practice. American journal of Psychiatry, 163(1), 28-40. 
9. Keller, M. B., Shapiro, R. W., Lavori, P. W., & Wolfe, N. (1982). Recovery in major depressive disorder: 
analysis with the life table and regression models. Archives of general psychiatry, 39(8), 905-910. 
10. Mathew, S. J. (2008). Treatment‐resistant depression: recent developments and future 
directions. Depression and anxiety, 25(12), 989-992. 
11. Nemeroff, C. B. (2007). Prevalence and management of treatment-resistant depression. Journal of Clinical 
Psychiatry, 68(8), 17. 
12. Pariante, C. M., & Lightman, S. L. (2008). The HPA axis in major depression: classical theories and new 
developments. Trends in neurosciences, 31(9), 464-468. 
	 27	
13. Nomikos GC, Damsma G, and Wenkstern D. et al. Acute effects of bupropion on extracellular dopamine 
concentrations in rat striatum and nucleus accumbens studied by in vivo 
microdialysis. Neuropsychopharmacology. 1989 2:273–279. 
14. Li SX, Perry KW, Wong DT. Influence of fluoxetine on the ability of bupropion to modulate extracellular 
dopamine and norepinephrine concentrations in three mesocorticolimbic areas of the 
rat. Neuropharmacology. 2002;42:181–190. 
15. Kitamura, Y., Araki, H., & Gomita, Y. (2002). Influence of ACTH on the effects of imipramine, 
desipramine and lithium on duration of immobility of rats in the forced swim test. Pharmacology 
Biochemistry and Behavior, 71(1), 63-69. 
16. Walker, A. J., Burnett, S. A., Hasebe, K., McGillivray, J. A., Gray, L. J., McGee, S. L., ... & Tye, S. J. 
(2013). Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and 
prefrontal monoamine tissue levels. Behavioural brain research, 242, 76-83. 
17. Kelly, W. F., Checkley, S. A., & Bender, D. A. (1980). Cushing's syndrome, tryptophan and 
depression. The British Journal of Psychiatry, 136(2), 125-132. 
18. Sonino, N., Boscaro, M., Ambroso, G., Merola, G., & Mantero, F. (1986). Prolonged treatment of 
Cushing’s Disease with metyrapone and aminoglutethimide. IRCS Medical Science-Biochemistry, 14(5), 
485-486. 
19. Dong, C., Wong, M. L., & Licinio, J. (2009). Sequence variations of ABCB1, SLC6A2, SLC6A3, 
SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in 
Mexican-Americans. Molecular psychiatry, 14(12), 1105-1118. 
20. Michelhaugh SK, Fiskerstrand C, Lovejoy E, Bannon MJ, Quinn JP. The dopamine transporter gene 
(SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J 
Neurochem. 2001;79:1033–1038. 
21. Philibert, R. A., Sandhu, H., Hollenbeck, N., Gunter, T., Adams, W., & Madan, A. (2008). The relationship 
of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and 
alcohol dependence in subjects from the Iowa Adoption Studies. American Journal of Medical Genetics 
Part B: Neuropsychiatric Genetics, 147(5), 543-549. 
	 28	
22. Tate, P. H., & Bird, A. P. (1993). Effects of DNA methylation on DNA-binding proteins and gene 
expression. Current opinion in genetics & development, 3(2), 226-231. 
23. Uddin, M. (2014). Blood-based biomarkers in depression: emerging themes in clinical research. Molecular 
diagnosis & therapy, 18(5), 469-482. 
24. Lopresti, A. L., Maker, G. L., Hood, S. D., & Drummond, P. D. (2014). A review of peripheral biomarkers 
in major depression: the potential of inflammatory and oxidative stress biomarkers. Progress in Neuro-
Psychopharmacology and Biological Psychiatry, 48, 102-111. 
25. Nestler, E. J., & Hyman, S. E. (2010). Animal models of neuropsychiatric disorders. Nature 
neuroscience, 13(10), 1161-1169. 
26. Uddin, M., Aiello, A. E., Wildman, D. E., Koenen, K. C., Pawelec, G., de Los Santos, R., ... & Galea, S. 
(2010). Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proceedings 
of the National Academy of Sciences, 107(20), 9470-9475. 
27. Goldmann, E., Aiello, A., Uddin, M., Delva, J., Koenen, K., Gant, L. M., & Galea, S. (2011). Pervasive 
exposure to violence and posttraumatic stress disorder in a predominantly African American Urban 
Community: the Detroit Neighborhood Health Study. Journal of traumatic stress, 24(6), 747-751. 
28. Hannon, E., Lunnon, K., Schalkwyk, L., & Mill, J. (2015). Interindividual methylomic variation across 
blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric 
phenotypes. Epigenetics, 10(11), 1024-1032. 
29. Paternain, L., Batlle, M. A., De la Garza, A. L., Milagro, F. I., Martinez, J. A., & Campion, J. (2012). 
Transcriptomic and epigenetic changes in the hypothalamus are involved in an increased susceptibility to a 
high-fat-sucrose diet in prenatally stressed female rats. Neuroendocrinology, 96(3), 249-260. 
30. Siuda, D., Wu, Z., Chen, Y., Guo, L., Linke, M., Zechner, U., ... & Li, H. (2014). Social isolation-induced 
epigenetic changes in midbrain of adult mice. J. Physiol. Pharmacol, 65, 247-255. 
31. Tost, J., & Gut, I. G. (2007). DNA methylation analysis by pyrosequencing. Nature protocols, 2(9), 2265-
2275. 
32. Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful 
approach to multiple testing. Journal of the royal statistical society. Series B (Methodological), 289-300. 
	 29	
33. Barfield, R. T., Kilaru, V., Smith, A. K., & Conneely, K. N. (2012). CpGassoc: an R function for analysis 
of DNA methylation microarray data. Bioinformatics, 28(9), 1280-1281. 
34. Chen, Y. A., Lemire, M., Choufani, S., Butcher, D. T., Grafodatskaya, D., Zanke, B. W., ... & Weksberg, 
R. (2013). Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium 
HumanMethylation450 microarray. Epigenetics, 8(2), 203-209. 
35. Pidsley, R., Wong, C. C., Volta, M., Lunnon, K., Mill, J., & Schalkwyk, L. C. (2013). A data-driven 
approach to preprocessing Illumina 450K methylation array data. BMC genomics, 14(1), 1. 
36. Teschendorff, A. E., Marabita, F., Lechner, M., Bartlett, T., Tegner, J., Gomez-Cabrero, D., & Beck, S. 
(2013). A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 
450 k DNA methylation data. Bioinformatics, 29(2), 189-196. 
37. Johnson, W. E., Li, C., & Rabinovic, A. (2007). Adjusting batch effects in microarray expression data 
using empirical Bayes methods. Biostatistics, 8(1), 118-127. 
38. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., Storey, J.D., 2012. The sva package for removing 
batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28(6), 882-883. 
39. Logue, M. W., Amstadter, A. B., Baker, D. G., Duncan, L., Koenen, K. C., Liberzon, I., ... & Smith, A. K. 
(2015). The Psychiatric Genomics Consortium Posttraumatic Stress Disorder Workgroup: posttraumatic 
stress disorder enters the age of large-scale genomic collaboration. Neuropsychopharmacology, 40(10), 
2287-2297. 
40. Aryee, M. J., Jaffe, A. E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A. P., Hansen, K. D., & Irizarry, 
R. A. (2014). Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA 
methylation microarrays. Bioinformatics, 30(10), 1363-1369. 
41. Barfield, R. T., Almli, L. M., Kilaru, V., Smith, A. K., Mercer, K. B., Duncan, R., ... & Ressler, K. J. 
(2014). Accounting for population stratification in DNA methylation studies. Genetic epidemiology, 38(3), 
231-241. 
42. Guintivano, J., Aryee, M. J., & Kaminsky, Z. A. (2013). A cell epigenotype specific model for the 
correction of brain cellular heterogeneity bias and its application to age, brain region and major 
depression. Epigenetics, 8(3), 290-302. 
	 30	
43. Sutherland, J. E., & Costa, M. A. X. (2003). Epigenetics and the environment. Annals of the New York 
Academy of Sciences, 983(1), 151-160. 
44. Koenen, K. C., Uddin, M., Chang, S. C., Aiello, A. E., Wildman, D. E., Goldmann, E., & Galea, S. (2011). 
SLC6A4 methylation modifies the effect of the number of traumatic events on risk for posttraumatic stress 
disorder. Depression and anxiety, 28(8), 639-647. 
45. Zhang, X., Wu, M., Xiao, H., Lee, M. T., Levin, L., Leung, Y. K., & Ho, S. M. (2010). Methylation of a 
single intronic CpG mediates expression silencing of the PMP24 gene in prostate cancer. The 
Prostate, 70(7), 765-776. 
46. Mercer, T. R., Dinger, M. E., & Mattick, J. S. (2009). Long non-coding RNAs: insights into 
functions. Nature Reviews Genetics, 10(3), 155-159. 
47. Lei, M. K., Beach, S. R., Simons, R. L., & Philibert, R. A. (2015). Neighborhood crime and depressive 
symptoms among African American women: Genetic moderation and epigenetic mediation of 
effects. Social Science & Medicine, 146, 120-128. 
48. Wang, D., Szyf, M., Benkelfat, C., Provençal, N., Turecki, G., Caramaschi, D., ... & Booij, L. (2012). 
Peripheral SLC6A4 DNA methylation is associated with in vivo measures of human brain serotonin 
synthesis and childhood physical aggression. PloS one, 7(6), e39501. 
49. Dalla, C., Pitychoutis, P. M., Kokras, N., & Papadopoulou-Daifoti, Z. (2010). Sex differences in animal 
models of depression and antidepressant response. Basic & clinical pharmacology & toxicology, 106(3), 
226-233. 
50. Marsh, W. K., & Deligiannidis, K. M. (2010). Sex-related differences in antidepressant response: When to 
adjust treatment. Current Psychiatry, 9(5), 25-30. 
51. Smalheiser, N. R., Lugli, G., Rizavi, H. S., Torvik, V. I., Turecki, G., & Dwivedi, Y. (2012). MicroRNA 
expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PloS 
one, 7(3), e33201. 
 
 
 
 
 
 	 	
